January 3, 2018 / 9:19 PM / 8 months ago

BRIEF-Ampliphi Biosciences Announces Positive Interim Results For Single-Patient Expanded Access Program For AB-SA01 And AB-PA01

Jan 3 (Reuters) - Ampliphi Biosciences Corp:

* AMPLIPHI BIOSCIENCES ANNOUNCES POSITIVE INTERIM RESULTS FOR SINGLE-PATIENT EXPANDED ACCESS PROGRAM UTILIZING AB-SA01 AND AB-PA01

* AMPLIPHI BIOSCIENCES CORP - TREATMENT WAS WELL TOLERATED IN ALL PATIENTS, WITH OVER 500 DOSES ADMINISTERED INTRAVENOUSLY OR BY INHALATION

* AMPLIPHI BIOSCIENCES CORP - SEVEN PATIENTS WITH SERIOUS INFECTIONS WERE TREATED WITH AB-SA01 OR AB-PA01, WITH 6 PATIENTS ACHIEVING TREATMENT SUCCESS

* AMPLIPHI BIOSCIENCES CORP - EXPECTS TO CONTINUE ITS EXPANDED ACCESS CLINICAL STRATEGY IN 2018, REVIEW DATA WITH FDA IN MID-2018

* AMPLIPHI BIOSCIENCES CORP - EXPECTS TO CONTINUE TO INITIATE A PHASE 2 OR REGISTRATIONAL CLINICAL PROGRAM POTENTIALLY AS EARLY AS SECOND HALF OF 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below